RxDoctor Payments Data

Piyush Mittal, MD

Internal Medicine · Lubbock, TXNPI 1447250923

Payments from drug & device makers

$9,264in general payments, 2019–2025

Across 556 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Novo Nordisk$681
  • Novartis$636
  • Abbott$583
  • Lilly USA, LLC$531
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$9,05198%
  • Education$2132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,264 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$470,549
Medicare patients
832
Services billed
17,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide13$576,102
OzempicSemaglutide169$176,853
MounjaroTirzepatide97$119,836
EliquisApixaban165$97,517
XifaxanRifaximin26$57,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$56,653
JardianceEmpagliflozin58$50,149
XareltoRivaroxaban26$33,888
JanumetSitagliptin Phos/Metformin Hcl16$26,828
Repatha SureclickEvolocumab31$25,246
JanuviaSitagliptin Phosphate37$23,377
TrulicityDulaglutide15$21,489
EntrestoSacubitril/Valsartan34$19,559
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$17,439
LinzessLinaclotide19$16,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$246$576,10213 claims
Novo NordiskOzempic$681$176,853169 claims
Lilly USA, LLCMounjaro, Trulicity$531$141,325112 claims
PfizerEliquis$49$97,517165 claims
GSKTrelegy Ellipta, Breo Ellipta$266$61,45485 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$115$57,89526 claims
MerckJanumet, Januvia$191$50,20553 claims
Boehringer IngelheimJardiance$211$50,14958 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$157$35,52052 claims
Johnson & JohnsonXarelto$368$33,88826 claims
NovartisEntresto$636$19,55934 claims
AbbVieLinzess$1,084$16,16819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →